

# Ya-Zhen Qin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3136650/publications.pdf>

Version: 2024-02-01

76  
papers

1,405  
citations

430874

18  
h-index

395702

33  
g-index

94  
all docs

94  
docs citations

94  
times ranked

1552  
citing authors

#	ARTICLE	IF	CITATIONS
1	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. <i>Blood</i> , 2013, 121, 4056-4062.	1.4	277
2	Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. <i>Annals of Hematology</i> , 2013, 92, 1111-1119.	1.8	87
3	Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center. <i>Leukemia Research</i> , 2014, 38, 1435-1440.	0.8	63
4	Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. <i>Annals of Hematology</i> , 2009, 88, 159-166.	1.8	51
5	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 44.	17.0	51
6	Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. <i>Leukemia Research</i> , 2006, 30, 1159-1165.	0.8	50
7	Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1110-1116.	2.0	44
8	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. <i>Stem Cells and Development</i> , 2017, 26, 1648-1661.	2.1	36
9	Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. <i>Blood</i> , 2018, 131, 2987-2989.	1.4	36
10	Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 741-750.	2.0	36
11	Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia. <i>Leukemia</i> , 2018, 32, 2285-2287.	7.2	32
12	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3116-3123.	1.3	31
13	Prevalence and outcomes of uncommon <i>t(8;21)BCR-ABL1</i> fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. <i>British Journal of Haematology</i> , 2018, 182, 693-700.	2.5	31
14	Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t(8;21). <i>Leukemia Research</i> , 2016, 44, 40-44.	0.8	29
15	Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABLIS or log reduction from the baseline level?. <i>Leukemia Research</i> , 2013, 37, 1035-1040.	0.8	28
16	Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia-Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 929-936.	2.0	28
17	The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. <i>Leukemia and Lymphoma</i> , 2017, 58, 1135-1143.	1.3	27
18	PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2013, 54, 1442-1449.	1.3	23

#	ARTICLE	IF	CITATIONS
19	Cysteine and glycine-rich protein 2 ( <i>CSRP2</i> ) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics. <i>Oncotarget</i> , 2017, 8, 35984-36000.	1.8	23
20	<i>PRAME</i> Gene Copy Number Variation Is Related to Its Expression in Multiple Myeloma. <i>DNA and Cell Biology</i> , 2017, 36, 1099-1107.	1.9	22
21	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). <i>Blood Cancer Journal</i> , 2018, 8, 76.	6.2	21
22	Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements. <i>Annals of Hematology</i> , 2017, 96, 567-574.	1.8	19
23	B-cell acute lymphoblastic leukemia associated with SET-NUP214 rearrangement: A case report and review of the literature. <i>Oncology Letters</i> , 2016, 11, 2644-2650.	1.8	18
24	Interferon- $\gamma$ Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. <i>Oncologist</i> , 2018, 23, 1349-1357.	3.7	17
25	High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy. <i>Medical Science Monitor</i> , 2018, 24, 758-767.	1.1	17
26	Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2016, 95, 1233-1240.	1.8	16
27	CD38+ CD58 <sup>+</sup> is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients. <i>Leukemia Research</i> , 2016, 43, 33-38.	0.8	16
28	The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 73-82.	1.8	15
29	Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients. <i>Medicine (United States)</i> , 2016, 95, e2486.	1.0	14
30	Interferon- $\gamma$ as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2949-2956.	1.3	14
31	Preemptive Interferon- $\gamma$ Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. <i>Frontiers in Immunology</i> , 2022, 13, 757002.	4.8	13
32	PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy. <i>Leukemia Research</i> , 2017, 52, 43-49.	0.8	12
33	The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 967-972.	1.3	12
34	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. <i>Chinese Journal of Cancer</i> , 2016, 35, 46.	4.9	11
35	Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL. <i>Journal of Translational Medicine</i> , 2017, 15, 184.	4.4	11
36	DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, 67-78.	2.5	11

#	ARTICLE	IF	CITATIONS
37	The Prognostic Significance of ZNF384 Fusions in Adult Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: A Comprehensive Cohort Study From a Single Chinese Center. <i>Frontiers in Oncology</i> , 2021, 11, 632532.	2.8	9
38	The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 67.	6.2	9
39	Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. <i>Leukemia Research</i> , 2017, 59, 136-141.	0.8	8
40	The prognostic significance of Wilms's tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2019, 98, 2551-2559.	1.8	8
41	Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3406-3418.	5.2	8
42	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Oncology</i> , 2021, 11, 773394.	2.8	8
43	Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia. <i>Methods in Molecular Biology</i> , 2016, 1465, 1-15.	0.9	7
44	A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype. <i>Leukemia Research</i> , 2018, 72, 12-19.	0.8	7
45	High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia. <i>Cancer Medicine</i> , 2019, 8, 5459-5467.	2.8	7
46	miR-100a-1 suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 836-851.	2.5	7
47	Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia. <i>Scientific Reports</i> , 2021, 11, 4856.	3.3	7
48	Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 163-168.	2.0	6
49	Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 1733-1742.	1.8	6
50	Prognostic significance of SET-NUP214 fusion gene in acute leukemia after allogeneic hematopoietic stem cell transplantation. <i>Medicine (United States)</i> , 2020, 99, e23569.	1.0	6
51	Wilms's tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. <i>BMC Cancer</i> , 2021, 21, 292.	2.6	5
52	Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 188-195.	2.8	4
53	Characterization of somatic mutation-associated microenvironment signatures in acute myeloid leukemia patients based on TCGA analysis. <i>Scientific Reports</i> , 2020, 10, 19037.	3.3	4
54	Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment. <i>Annals of Hematology</i> , 2021, 100, 2557-2566.	1.8	4

#	ARTICLE	IF	CITATIONS
55	Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 152-161.	1.3	4
56	Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype. <i>International Journal of Laboratory Hematology</i> , 2022, , .	1.3	4
57	Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes. <i>Oncology Letters</i> , 2017, 13, 2823-2830.	1.8	3
58	Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib. <i>Leukemia and Lymphoma</i> , 2017, 58, 1384-1393.	1.3	3
59	Overexpressed WT1 exhibits a specific immunophenotype in intermediate and poor cytogenetic risk acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 215-221.	1.8	3
60	High PRDM16 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk: a comprehensive cohort study from a single Chinese center. <i>Leukemia and Lymphoma</i> , 2021, 62, 185-193.	1.3	3
61	Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 1267-1281.	1.8	3
62	PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study. <i>British Journal of Haematology</i> , 2021, 195, 722-730.	2.5	3
63	Both Methylation and Copy Number Variation Participated in the Varied Expression of PRAME in Multiple Myeloma. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7545-7553.	2.0	2
64	Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>BMC Cancer</i> , 2022, 22, 11.	2.6	2
65	Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. <i>Hematological Oncology</i> , 2022, 40, 724-733.	1.7	2
66	Low EVI1 expression at diagnosis predicted poor outcomes in pediatric Ph-negative B cell precursor acute lymphoblastic leukemia patients. <i>Pediatric Hematology and Oncology</i> , 2022, 39, 97-107.	0.8	1
67	ATRA Could Correct the Defective S1P-Mediated Cytoskeletal Reorganization in Proplatelet Formation of ITP. <i>Blood</i> , 2019, 134, 218-218.	1.4	1
68	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: To Allogeneic Stem Cell Transplantation or Not? a Single Center Experience. <i>Blood</i> , 2016, 128, 2308-2308.	1.4	1
69	Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL. <i>Annals of Hematology</i> , 2018, 97, 799-811.	1.8	0
70	Imatinib Mesylate Versus Allogeneic HSCT for Patients with Chronic Myelogenous Leukemia In Accelerated Phase: A Single Center Experience In China After a 9-Year Follow-up. <i>Blood</i> , 2010, 116, 2347-2347.	1.4	0
71	Low WT1 Expression At Diagnosis Is a Strong Predictor On Poor Outcome In Patients With t(8;21) Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1346-1346.	1.4	0
72	Prevalence and Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Comprehensive Large-Scale Study from a Single Chinese Center. <i>Blood</i> , 2014, 124, 1000-1000.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Janus Kinase Inhibition By Ruxolitinib Combined with Nilotinib Has Superior Anti-Leukemia Propagating Cells Effect in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 4023-4023.	1.4	0
74	C-KIT- Mutated t(8;21)AML Patients with >3log Reduction of MRD Conferred a Very High Relapse and Need HSCT to Improve Outcome. <i>Blood</i> , 2016, 128, 1620-1620.	1.4	0
75	Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia. <i>Hematology</i> , 2021, 26, 9-15.	1.5	0
76	Prognostic value of post-transplantation Wilms' tumor gene 1 expression in acute myeloid leukaemia subgroup according to different pre-transplant disease status. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	1.3	0